Anthropic's Claude cuts a three-month regulatory filing to four hours
Early progress on accelerating drug development with Claude
Anthropic's life sciences team partnered with six drug developers — including Bristol Myers Squibb, Generate Biomedicines, and BigHat Biosciences — plus acquired a one-person startup to test Claude across real drug programs. Results span 70% shorter CAR-T constructs that produced 10x more receptors, 35,000 antibody designs generated in a month, and manufacturing paperwork review that caught every human-flagged issue plus seven more while cutting review time 89%. Most work remains preclinical.
Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted—and flagged seven they'd missed.